- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02021123
Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) (ADOPT)
Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery.
Because anidulafungin is generally well tolerated and appears to have limited interaction with other drugs, it is a potential important agent in the treatment of invasive fungal infections. Although anidulafungin is approved for the treatment of invasive candidiasis in adult non-neutropenic patients, dosing guidelines for anidulafungin in (morbidly) obese patients are not available. Subsequently, the pharmacokinetic profile of anidulafungin (as well as other echinocandins) in this specific patient population is still largely unknown. During endoscopic gastric bypass surgery, patients are more prone to various kinds of infection, justifying the prophylactic use of anidulafungin in this specific cohort of patients.
To build a valid pharmacokinetic model, obese patients with a BMI ≥ 40 undergoing endoscopic gastric bypass surgery will receive a single dose of 100 mg anidulafungin (besides standard anti-bacterial prophylaxis) and a PK-curve will be drawn. These PK-values can then be compared to the pharmacokinetics in a normal-weight group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nieuwegein, Netherlands
- St. Antonius Hospital
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands
- Radboud University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has a BMI ≥40 kg/m2 and is undergoing endoscopic gastric bypass surgery.
- Subject is at least 18 years of age on the day of screening.
- If subject is female: neither pregnant, nor able to become pregnant and is not nursing an infant.
- Subject or legal representatives are able and willing to sign the Informed Consent before screening evaluations.
Exclusion Criteria:
- Documented history of sensitivity to medicinal products or excipients similar to those found in the echinocandin preparation.
- History of, or current abuse of drugs, alcohol or solvents.
- Inability to understand the nature of the trial and the procedures required.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Anidulafungin 100 mg single dose
100 mg single dose anidulafungin pre-surgery (gastric bypass)
|
Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anidulafungin area under the curve
Time Frame: 0-72 h after single dose
|
The primary outcome measurement will be the area under the plasma concentration-time curve (AUC) from time 0 to infinitive (inf) post infusion (AUC0- inf) value of anidulafungin.
This will be determined by use of the log-linear trapezoidal rule.
Peak plasma concentrations (Cmax) will be directly observed from the data.
The elimination rate constant will be determined by linear regression of the terminal points of the log-linear plasma concentration time curve.
Clearance (CL) will be calculated as dose/AUC0- inf.
|
0-72 h after single dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predict long-term exposure after repeated dosing by using a pharmacokinetic model of anidulafunign in obese patients by using AUC(0-inf), Cmax, elimination half-life and clearance.
Time Frame: PK curve on day 1-3
|
Simulate pharmacokinetics of anidulafungin after obtaining all plasma concentrations using modeling software to predict long-term exposure.
For this, area under the plasma concentration-time curve (AUC) from time 0 to infinitive (inf) post infusion (AUC0- inf), peak plasma concentration (Cmax), elimination half-life and clearance values of anidulafungin will be used (as calculated in outcome measure 1).
The PK curve of day 1-3 will serve to calculate these values.
|
PK curve on day 1-3
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events
Time Frame: 0-72 h after dosing
|
adverse events will be collected and reported
|
0-72 h after dosing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roger JM Brüggemann, PharmD, PhD, Radboud University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCN-AKF 13.06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity Morbid
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
Centre Hospitalier Universitaire de NiceCompletedMorbid Obesity D009765France
-
Shanghai Jiao Tong University School of MedicineUnknown
-
Hospices Civils de LyonCentre de Recherche en Nutrition Humaine Rhone-Alpe; Institut National de Recherche... and other collaboratorsRecruiting
-
Endolumik, IncWest Virginia UniversityNot yet recruitingMorbid ObesityUnited States
-
Rijnstate HospitalRecruiting
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Recruiting
-
University of WashingtonUnited States Department of DefenseWithdrawn
-
Helsinki University Central HospitalActive, not recruiting
-
IHU StrasbourgWithdrawnMorbid Obesity
Clinical Trials on Anidulafungin 100mg single dose iv
-
AblynxCompletedHealthy VolunteersUnited States
-
National and Kapodistrian University of AthensUnknownHip Fractures | Blood Loss, Surgical | Complication, PostoperativeGreece
-
GlaxoSmithKlineCompletedAsthmaUnited Kingdom
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...CompletedHealthy | HIVUnited States, Germany
-
GlaxoSmithKlineCompletedRespiratory DisordersUnited Kingdom
-
Yuhan CorporationCompleted
-
Rockefeller UniversityUniversity of CologneCompletedHealthy | HIVGermany, United States
-
Medicines for Malaria VentureCross Research S.A.Completed
-
Novartis PharmaceuticalsCompletedSchizophrenia DisordersUnited States
-
PfizerCompletedFungal InfectionNetherlands